Axsome Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M |
| Operating expenses | — | — | — | — | $124.7M |
| Cost of revenue | — | — | — | $5.2M | — |
| Cash from operations | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M |
| Capital expenditure | $480,000 | $270,000 | $582,000 | $702,000 | $308,000 |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M |
| Total debt | $120.0M | $180.0M | $180.0M | $95.0M | $50.0M |
Shares outstanding 51.5M · Free float 63.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.